A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Hôpital Erasme/Erasmus Ziekenhuis, Brussels

UZ Antwerpen, Edegem

Seoul National University Hospital, Seoul

CHU de Liège, Liège

Taipei Veterans General Hospital, Taipei

Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia, Rozzano

IRCCS Foundation Istituto Neurologico Carlo Besta, Milan

ASST Grande Ospedale Metropolitano Niguarda - Oncologia Falck, Milan

Institut Claudius Regaud - iUCT Oncopole, Toulouse

Institut Bergonie - Unicancer Nouvelle Aquitaine, Bordeaux

Moffitt Cancer Center, Tampa

Istituto Oncologico Veneto_Padova - UOC Oncologia 1, Padua

Sarah Cannon Cancer Center, Nashville

AUSL di Bologna_Istituto delle Scienze Neurologiche - UO Oncologia del Sistema Nervoso, Bologna

Institut de Cancerologie Ouest - Saint-Herblain, Saint-Herblain

UNICANCER - Centre Leon Berard (CLB), Lyon

Chi Mei Medical Center, Taikang

Baylor Charles A. Sammons Cancer Center at Dallas, Dallas

APHP-Hopital la Pitie Salpetriere, Paris

University of Texas MD Anderson Cancer Center, Houston

Rocky Mountain Cancer Centers / Aurora, CO, Aurora

City of Hope - Duarte Cancer Center, Duarte

Gustave Roussy - Departement Oncologie-Radiotherapie, Villejuif

China Medical University Hospital, Taichung

Aichi Cancer Center Hospital, Nagoya

Kobe University Hospital, Kobe

Saitama Cancer Center, Kitaadachi-gun

National Cancer Center Hospital, Chuo-ku

The Cancer Institute Hospital of JFCR, Koto-ku

Severance Hospital, Yonsei University Health System, Seoul

Royal Marsden NHS Trust (Surrey), Sutton

University Hospitals Coventry and Warwickshire NHS Trust, Coventry

Beatson West of Scotland Cancer Centre, Glasgow

"The Royal Marsden NHS Foundation Trust , The Royal Marden Hospital - The Royal Marsden Clinical Trials Unit (CTU)"